What is a US patent application for biosynthesis of retinoids?

It is a legal filing with the US Patent and Trademark Office (USPTO) that describes a novel, non-obvious, and useful method for producing retinoids (like retinol or retinal) using genetically engineered microorganisms or enzymes, rather than traditional chemical synthesis.

What are the key requirements for patenting a biosynthesis method for retinoids?

The method must be novel, non-obvious, and have industrial applicability. It typically requires demonstrating a specific engineered pathway, such as a modified yeast or bacterial strain, that produces retinoids at a commercially viable yield or purity.

Can naturally occurring organisms be patented for retinoid biosynthesis?

No, naturally occurring organisms cannot be patented. However, genetically modified organisms (GMOs) with unique, non-naturally occurring genetic constructs for retinoid production may be patentable if they meet novelty and non-obviousness criteria.

How long does a US patent application for retinoid biosynthesis take to process?

The USPTO examination process typically takes 1 to 3 years from filing to issuance, though it can vary based on the complexity of the claims and any office actions or appeals.

What prior art is commonly cited against retinoid biosynthesis patent applications?

Common prior art includes published scientific papers on metabolic engineering of microbes for isoprenoid or carotenoid production, existing patents on retinoid synthesis pathways, and known enzyme variants used in terpenoid biosynthesis.

US Patent Application Biosynthesis of Retinoids Guide

A patent application for the biosynthesis of retinoids describes a method for producing these vitamin A derivatives inside a living cell, typically a microorganism like yeast or bacteria, rather than through traditional chemical synthesis. The core of such an application is the genetic modification of a host organism to express a specific set of enzymes that convert a simple, renewable feedstock into the target retinoid compound. This guide explains the key components you will find in a typical filing, from genetic engineering strategies to production yield claims.

The Core Invention: Engineering a Cellular Factory

The primary claim is the creation of a genetically modified host cell that produces a retinoid. The invention replaces multi-step chemical reactions, which often require hazardous solvents and produce low yields, with a single biological process.

The Retinoid Biosynthetic Pathway

The pathway typically involves three main stages:

Building the precursor: The cell is modified to increase its natural production of geranylgeranyl diphosphate (GGPP), a common isoprenoid building block.
The key condensation step: A specific enzyme, often a phytoene synthase from a plant or fungus, joins two GGPP molecules to create phytoene, the first dedicated carotenoid in the pathway.
Desaturation and conversion: Desaturase enzymes convert phytoene into lycopene, then into beta-carotene. A beta-carotene 15,15’-dioxygenase (BCO) cleaves beta-carotene to produce retinaldehyde, which can then be reduced to retinol or oxidized to retinoic acid.

The application specifies the exact enzyme names (e.g., CrtB for phytoene synthase) and the source organism. It also includes variants of these enzymes that show improved activity.

The Host Organism and Genetic Construct

Common host cells include Saccharomyces cerevisiae (baker’s yeast) and Escherichia coli. The application describes the genetic construct used to insert the pathway genes into the host, including regulatory elements like strong promoters that control enzyme production. The goal is to maximize carbon flux through the pathway into the final retinoid product.

Fermentation and Production Methods

The patent claims the process for growing the engineered microorganism and producing the retinoid. This section is critical because commercial value lies in scale-up capability.

Key Process Parameters

The specification describes fermentation conditions optimized for yield:

Carbon source: Feedstock such as glucose, glycerol, or sucrose.
Temperature and pH: Optimal ranges for cell growth and enzyme activity.
Induction timing: For inducible systems, the point when pathway gene expression is triggered.
Aeration and agitation: Oxygen supply is critical for desaturation steps.

A worked example might state that under fed-batch fermentation with a glucose feed, the engineered yeast strain produced 1.5 grams of beta-carotene per liter of culture after 120 hours. These yield numbers are the most valuable data in the application.

Downstream Processing

The application outlines recovery methods, which may include:

Cell harvesting by centrifugation or filtration.
Cell disruption to release intracellular product.
Solvent extraction using an organic solvent like hexane or ethyl acetate.
Purification steps such as crystallization or chromatography.

Composition and Product Claims

Patent applications often include claims directed to the final product. For retinoid biosynthesis, this can be a composition containing the retinoid produced by the engineered cell.

Purity and Isotopic Labeling

A key distinction from chemically synthesized retinoids is potential isotopic labeling. If the feedstock is enriched with a stable isotope like carbon-13, the resulting retinoid will also be labeled. The patent may claim a retinoid composition with a specific isotopic signature characteristic of biosynthesis.

The application might also claim a composition with a defined purity profile. For example, retinol produced by the method that is at least 95% pure by HPLC analysis.

Challenges in Pathway Optimization

Simply inserting pathway genes into a host cell rarely produces high yields. The application describes common problems and solutions.

Metabolic Flux and Competing Pathways

The engineered cell uses its GGPP precursor for other functions, like making sterols in yeast. The patent claims modifications to reduce these competing pathways, such as downregulating native squalene synthase to divert carbon toward retinoid synthesis.

Another challenge is accumulation of toxic intermediates like lycopene. The patent may claim a method for balancing desaturase enzyme expression to prevent buildup, using promoters of different strengths for each gene.

Enzyme Engineering

To improve yield, the patent may describe modified enzymes with specific amino acid substitutions that increase activity or stability. Directed evolution also appears in these applications, where a library of random mutations is screened for higher activity, and the best performer is isolated.

Analytical Methods

The specification includes methods for identifying and quantifying the retinoid product, essential for proving the invention works.

Chromatographic Separation

High-performance liquid chromatography (HPLC) with a diode array detector or mass spectrometer is used. Retinoids have distinct UV-visible absorption spectra. The patent includes specific HPLC methods, including column type, mobile phase composition, and gradient program.

Structural Confirmation

Nuclear magnetic resonance (NMR) spectroscopy may confirm product identity. The application states that proton and carbon NMR spectra match an authentic standard, strengthening the enablement requirement.

Key Takeaways

A patent for retinoid biosynthesis centers on a genetically modified microorganism that expresses a multi-step enzyme pathway to convert a simple sugar into a retinoid.
The application must clearly identify the specific genes (e.g., phytoene synthase, desaturases, BCO) and the host organism.
Process claims covering fermentation conditions and downstream recovery methods are essential for commercial protection.
Product claims can cover the retinoid composition itself, often defined by its purity or a unique isotopic signature from the biological process.
The yield data from worked examples is the most concrete evidence of the invention’s utility and is a critical part of any strong application.

Guide to US Patent Application Biosynthesis of Retinoids